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Abstract
Background: Human paraoxonase 1 (PON1) is an HDL-associated enzyme with anti-oxidant/anti-inflammatory
properties that has been suggested to play an important protective role against coronary heart diseases and
underlying atherogenesis. The common PON1 Q192R polymorphism (rs662, A>G), a glutamine to arginine
substitution at amino acid residue 192, has been analyzed in numerous association studies as a genetic marker for
coronary heart diseases, however, with controversial results.
Findings: To get a better understanding about the pathophysiological function of PON1, we analyzed the
relationships between the Q192R polymorphism, serum paraoxonase activity and serum biomarkers important for
atherogenesis. Genotyping a cohort of 49 healthy German males for the Q192R polymorphism revealed an allele
distribution of 0.74 and 0.26 for the Q and R allele, respectively, typical for Caucasian populations. Presence of the
R192 allele was found to be associated with a significantly increased paraoxonase enzyme activity of 187.8 ± 11.4
U/l in comparison to the QQ192 genotype with 60.5 ± 4.9 U/l. No significant differences among the genotypes
were found for blood pressure, asymmetric dimethylarginine, LDL, HDL, triglycerides, and cholesterol. As expected,
MIP-2 alpha a cytokine rather not related to atherosclerosis is not affected by the PON1 polymorphism. In contrast
to that, the pro-inflammatory cytokine TNF-alpha is enhanced in R192 carriers (163.8 ± 24.7 pg/ml vs 94.7 ± 3.2 pg/
ml in QQ192 carriers).
Conclusions: Our findings support the hypothesis that the common PON1 R192 allele may be a genetic risk factor
for atherogenesis by inducing chronic low-grade inflammation.
Introduction
Paraoxonase 1 (PON1) is a calcium-dependent enzyme
exhibiting esterase, lactonase and peroxidase activity. It
accepts a broad range of substrates including organo-
phosphates, diverse lactones and lipid peroxides and has
been studied for its ability to breakdown pesticides and
nerve gases. PON1 is a glycoprotein of about 45 kDa
that is predominantly synthesized by the liver, from
where it is distributed to other tissues, mainly to serum
[1,2]. In serum, PON1 is associated with high-density-
lipoprotein (HDL) particles [3]. HDL-associated PON1
has been frequently shown to have anti-oxidant and
anti-inflammatory potential mainly by protecting lipids
of HDLs and low-density lipoproteins (LDL) from oxida-
tive modifications [1,2]. Most likely, these protective
effects depend on the peroxidase and esterase activity of
PON1 allowing the detoxification of oxidized molecules
such as phospholipids and lipid hydroperoxides [4,5].
Cardiovascular diseases and underlying atherosclerosis
are associated with oxidative stress and inflammation.
Hence, serum PON1 is suggested to contribute to the
established anti-atherogenic function of HDLs which is,
at least partly, attributable to their anti-oxidative proper-
ties [1,2,6].
This notion is further supported by animal model stu-
dies using PON1 knock out and transgenic PON1 over-
expressing mice. HDLs of PON1-/- knock-out mice were
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found to prevent LDL oxidation less efficient than LDLs
from control mice [7]. On the other hand, increased
PON1 content in transgenic mice overexpressing murine
or human PON1 resulted in HDLs that were more pro-
tected from lipid peroxidation [8,9]. Moreover, PON1
deficiency in mice resulted in elevated levels of oxidative
stress and endothelial adhesion molecules [10]. Accord-
ingly, PON1-/- animals exhibited increased susceptibility
to the development of large atherosclerotic lesions on a
high-fat diet [7], whereas mice overexpressing human
PON1 exhibited decreased atherosclerotic lesion sizes
when fed an atherogenic diet [8,9].
The human PON1 gene is located on the long arm of
chromosome 7 between q21 and q22. Two common
coding region polymorphisms occur: a glutamine to
arginine substitution at position 192 (Q192R) which
affects PON1 enzyme activity and is analyzed in this
study, and a leucine to methionine substitution at posi-
tion 55 (L55M) [11]. PON1 gene polymorphisms have
been examined with respect to their association to var-
ious human diseases including coronary heart disease
(CHD), Parkinson’s disease, type 2 diabetes and inflam-
matory bowel disease [12,13]. Most studies focused on
the anti-oxidant/anti-inflammatory properties of PON1
in association with the development of atherosclerosis
and the role of the Q192R polymorphism as a genetic
marker for CHD. However, the results reported so far
are controversial, some indicating an association
between the Q192R polymorphism and atherosclerosis
and CHD risk, while others do not as reviewed in
[12,13].
In the present study, we have analyzed the influence
of the PON1 Q192R polymorphism on serum lipids and
inflammatory biomarkers in a cohort of 49 healthy male
individuals to get a better understanding of the role of
the PON1 Q192R polymorphism in the development of
atherosclerosis and CHD.
Materials and methods
Participants and study design
The cohort of 53 healthy males investigated in the pre-
sent study has been recently described [14]. In short,
based on clinical laboratory tests, the participants aged
between 21 and 48 had an average Body Mass Index
(BMI) of 24.1 ± 2.5 and fulfilled four criteria: (i) no his-
tory of gastrointestinal, hepatic, cardiovascular or renal
disease, (ii) no supplemental vitamin use for ≥ 2 weeks
before the start of the study, (iii) non- or occasional
smoking (≤ 3 cigarettes/day), and (iv) perpetuation of
usual nutrition habits. Fasting blood samples were taken
from each participant for genotyping, PON1 enzyme
activity determination and inflammatory biomarker ana-
lyses. The study was approved by the ethics committee
of the Medical Faculty of Kiel University, Germany,
(permission number A121/07) and was conformed to
Helsinki Declaration. All volunteers gave written
informed consent prior to participation.
Genotyping
Genomic DNA was isolated from whole blood samples.
Genotyping of the PON1 Single Nucleotide Polymorph-
ism (SNP) A/A, A/G, G/G (rs662) responsible for the
Q192R substitutions was performed by using the Taq-
Man system. Fluorescence was measured with ABI
Prism 7900 HT sequence detection system (ABI, Foster
City, USA).
PON enzyme activity assay
PON enzyme activity was determined spectrophotome-
trically in plasma samples following the protocol
described in [15]. Briefly, the rate of hydrolysis of para-
oxon (diethyl-p-nitrophenyl phosphatate; Supelco) was
measured by monitoring the increase of absorbance at
405 nm using 100 mM Tris-HCl (pH 8.0), 1 mM para-
oxon and 2 mM CaCl2. One unit of PON activity is
defined as 1 nmol of 4-nitrophenol formed per minute
at 20 °C under standard assay conditions (ε = 17600 M-
1 cm-1).
Serum biomarkers
Supernatants of whole blood samples were measured
with commercially available ELISA kits for TNF-alpha,
MCP-1 (R&D Systems, Minneapolis, MN), oxLDL
(KAMIYA Biomedical Company, Seattle, USA), asym-
metric dimethylarginine (ADMA) (DLD Diagnostika,
Hamburg, Germany) and MIP-2-alpha (Promocell,
Heidelberg, Germany). Optical density was read on a
microplate reader (Spectramax® 190, Molecular
Devices). Laboratory measurements including serum
lipid concentrations have been described previously [16].
Statistical analysis
Results are displayed as means ± SEM. Data were ana-
lyzed by an unpaired two-sided Student’s t-test (Micro-
soft Excel Version 2003 or GraphPad Prism 4.0
software). P-values < 0.05 were considered statistically
significant.
Results
Genotype distribution and basic characteristics
Genotype analysis of the PON1 Q192R polymorphism
(rs662, A>G) of 53 male volunteers revealed 25 homo-
zygous for Q/Q (51%), 23 heterozygous for Q/R (47%)
and 1 homozygous for R/R (2%), while 4 probes failed
genotyping. Because of the small incidence, in further
studies the G/G genotype (phenotype R/R) was com-
bined with the A/G genotype (phenotype Q/R) group.
Basic characteristics of the cohort have been recently
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reported by our group [14]. Briefly, the values for age
(30.13 ± 6.71 years), weight (79.11 ± 10.17 kg), height
(1.81 ± 0.06 m), BMI (24.12 ± 2.50 kg/m2) and fasting
glucose level (86.47 ± 10.68 mg/dl) as well as for the
kidney and liver parameters creatinine (1.05 ± 0.10 m/
dl), aspartate aminotransferase (30.09 ± 8.67 U/l), glu-
tamate pyruvate transaminase (37.79 ± 14.73 U/l) and
g-glutamyl transpeptidase (20.49 ± 10.36 U/l) were in
accordance with the inclusion criteria of the study and
show values within the physiological range for healthy
men.
Effect of the Q192R polymorphism on PON1 activity
PON1 enzyme activity was found to be significantly ele-
vated in the serum of Q/R and R/R individuals with a
mean value of 187.8 ± 11.4 U/l, when compared to the
Q/Q group having a mean value of 60.5 ± 4.9 U/l (p <
0.001; unpaired two-sided Student’s t-test) (Figure 1).
These data confirm previous studies that have demon-
strated a similar effect of the Q192R polymorphism on
serum PON1 activity [4,15].
Effect of the Q192R polymorphism on blood pressure and
ADMA
Subsequently we analyzed a possible association between
the Q192R polymorphism and blood pressure. However,
no significant differences for blood pressure and ADMA
levels, a blood pressure biomarker, were found between
the Q/Q and the combined Q/R + R/R group with
mean values of 82.5 ± 2.0 versus 82.9 ± 1.9 for diastolic
and 125.0 ± 2.4 versus 128.0 ± 2.6 for systolic pressure
as well as 0.96 ± 0.05 versus 0.98 ± 0.07 μmol/l for
ADMA.
Effect of the Q192R polymorphism on serum lipoproteins
and lipids
The Q192R polymorphism had no significant effect on
HDL (51.7 ± 2.8 versus 50.8 ± 2.4 mg/dl), LDL (95.8 ± 5.7
versus 92.8 ± 6.1 mg/dl), triglycerides (TG) (91.0 ± 8.1 ver-
sus 102.9 ± 11.6 mg/dl) and cholesterol (165.7 ± 5.1 versus
164.1 ± 6.7 mmol/l). In addition, we found a slight but not
significant increase in the oxLDL levels for the Q/R + R/R
group with a mean of 21.7 ± 2.8 U/ml compared to Q/Q
individuals with a mean value of 17.8 ± 3.0 U/ml.
Effect of the Q192R polymorphism on inflammatory
biomarkers
Finally, we analyzed the effect of the Q192R polymorph-
ism on the inflammatory biomarkers TNF-alpha, MCP-1
and MIP-2-alpha. As shown in Figure 2A, the mean
level of TNF-alpha for the Q/Q group was found to be
94.7 ± 3.2 pg/ml. In the sera of Q/R and R/R individuals
the respective level was significantly enhanced with a
mean value of 163.8 ± 24.7 pg/ml (p = 0.007; unpaired
two-sided Student’s t-test). Furthermore, the inflamma-
tory biomarker MCP-1 was slightly but not significantly
enhanced in Q/R and R/R individuals when compared
with the Q/Q group (202.0 ± 30.7 versus 173.0 ± 11.2
ng/ml) (Figure 2B). In contrast to that, MIP-2-alpha
levels were not affected by the Q192R polymorphism
(258.2 ± 13.7 versus 248.1 ± 12.9 pg/ml; Figure 2C).
Discussion
The role of the PON1 Q192R polymorphism in cardio-
vascular diseases is still under debate [1,2,12,13]. In the
present study, genotyping of a cohort of 49 German
males revealed a frequency of 0.74 for the Q192 allele
confirming previous reports on Western populations
with Caucasian origin [17-20]. Moreover, we found that
the occurrence of the R192 allele led to an elevated
serum paraoxonase activity which is also in good accor-
dance with previously published data on the Q and R
allozymes [21,22]. In this regard it is noteworthy that
paraoxon represents a non-natural substrate and that
the natural substrate(s) of PON1 has/have not been
identified so far [2]. Consequently, it is not a contradic-
tion that elevated specific paraoxonase activities of
PON1 allozymes have been demonstrated to be nega-
tively correlated with their antioxidant capacity in
HDLs, i.e. protecting LDLs against oxidation, reversing
the biological effects of oxidised LDLs and preserving
the function of HDLs [13,21,22]. Since the oxidation of
LDL and the accompanied formation of foam cell layers
are thought to represent crucial steps in the initiation
process of atherosclerosis [23,24], an enhanced antioxi-
dant activity of HDLs has been suggested to prevent
atherosclerosis and CHD [1,2]. Accordingly, a low-active
paraoxonase allele such as PON1 Q192 should protect
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Figure 1 Effect of the PON1 Q192R polymorphism on serum
PON1 enzyme activity. PON1 activity was determined in the sera
of Q/Q (n = 25) and Q/R+R/R (n = 24) male individuals under
standard assay conditions using paraoxon as substrate. Data
represent means ± SEM (*** p ≤ 0.001).
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against atherosclerosis when compared with the corre-
sponding high-active R192 allele. Although such an
association has been found in some studies
[17-19,25-31], no relationship has been revealed by
others [20,32-38]. Recent meta-analyses suggested a
weak association between the PON1 Q192R polymorph-
ism and CHD risk [39], however, no or only a popula-
tion-specific effect of the R192 allele on human
longevity [40]. Here we addressed the question whether
the Q192R polymorphism and the related differences in
PON1 activity are linked to changes in biomarkers indi-
cative for a pro-atherogenic status.
Our analyses revealed that PON1 genotypes are not
associated with alterations in blood pressure and
ADMA levels, elevation of both are linked with athero-
sclerosis [41]. Moreover, there were no differences in
the serum lipid profiles including TG, HDL, LDL and
cholesterol, except for slightly but not significantly
enhanced oxLDL levels. Similar results for TG, HDL,
LDL and cholesterol have been reported previously
[19,20,25,29,31-34,36-38], whereas a few studies found a
more pro-atherogenic serum lipid and/or lipoprotein
pattern in association with the R192 allele [35,42]. The
principal finding of this study is that the frequency of
the low-antioxidant R192 allele is associated with signifi-
cantly increased levels of the pro-inflammatory cytokine
TNF-alpha. Since chronic low grade alterations of
inflammatory markers are known to be associated with
increased atherogenic risk [43], elevated R192 allele-
dependent TNF-alpha levels may thus represent a puta-
tive risk marker.
Only recently, it has been demonstrated that adeno-
virus-based overexpression of human PON1 in apolipo-
protein E knock-out mice caused enhanced serum anti-
oxidative and anti-inflammatory capabilities reflected
among other factors by decreased TNF-alpha levels [44].
Hence, enhanced PON1 antioxidant capacity was found
to be associated with reduced TNF-alpha levels, prob-
ably protective against atherosclerosis. Considering the
anti-oxidant property of HDL-associated PON1, it is
intriguing to speculate that low amounts of serum
PON1 or low-anti-oxidant PON1 alleles such as R192
lead to elevated levels of reactive oxygen species in this
way triggering the redox-sensitive NfkappaB signaling
pathway that is known to stimulate TNF-alpha expres-
sion. However, further mechanistic investigations are
necessary to decipher this proposed PON1 TNF-alpha
relationship. It is remarkable that, in turn, enhanced
TNF-alpha levels have been shown to down-regulate
PON1 expression in murine and human hepatoma cell
lines as well as in vivo in mice, most probably via an
NF-kappaB- and nuclear receptor peroxisome prolifera-
tor-activated receptor-alpha (PPAR-alpha)-dependent
mechanism thereby diminishing the antioxidant and
anti-atherogenic activity of HDLs [45,46]. Moreover, a
TNF-alpha antagonist therapy in rheumatoid arthritis
patients led to enhanced PON1 levels concurrent with
elevated anti-oxidative capacities of HDLs and lowered
inflammatory status [47]. Interestingly, anti-TNF-alpha
therapy response was found to be associated with SNPs
in the PON1 locus [48] and a recent case-control study
on atherosclerosis in rheumatoid arthritis found a
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Figure 2 Effect of the PON1 Q192R polymorphism on inflammatory biomarkers. (A) TNF-alpha, (B) MCP-1 and (C) MIP-2-alpha levels were
determined in the sera of Q/Q (n = 25) and Q/R+R/R (n = 24) male subjects. Data represent means ± SEM (** p ≤ 0.01).
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correlation between PON-1 activity and serum TNF-
alpha and IL-6 levels [49], emphasizing the close regula-
tory interrelation between PON1 activity and TNF-alpha
levels.
In addition to TNF alpha, we found that levels of a
second pro-inflammatory cytokine MCP-1 were slightly
although not significantly enhanced in R192 carriers
that usually express PON1 allozymes with less antioxi-
dant capacity. MCP-1 expression and secretion of
endothelial cells are known to be induced by oxidized
LDL and accordingly, are thought to represent a crucial
step in the initial phase of the inflammatory processes
in atherosclerosis [43]. Consistent with its anti-oxidant
function that leads to reduced lipid peroxidation, PON1
has been demonstrated to attenuate MCP-1 expression
of cultured endothelial cells [50]. In good accordance
with that are data on HDLs isolated from wild type and
PON1 knock-out mice. In a human endothelial cell cul-
ture model PON1-/- HDLs exhibited significantly less
antioxidant capacity accompanied with elevated MCP-1
levels, hence, linking PON1 deficiency to lipid hydroper-
oxide-triggered expression of pro-inflammatory MCP-1
[7]. Since the amount of MIP-2 alpha, a cytokine rather
not related to atherosclerosis, is not affected by PON1
polymorphism, the observed changes of TNF-alpha and
MCP-1 levels observed in the current study are most
likely specific.
Conclusion
Our data indicate that the low-antioxidant PON1 R192
allele is associated with increased pro-inflammatory
cytokines known to be involved in the initiation process
of atherosclerosis. However, our finding needs to be
confirmed in further studies and especially in larger
study population.
Abbreviations used
ADMA: asymmetric dimethylarginine; CHD: coronary
heart disease; PON1: paraoxonase 1; SNP: single nucleo-
tide polymorphism; TG: triglycerides.
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